At present, glycosylated proteins have become one of the most common tumor biomarkers in clinic [16], such as alpha fetoprotein (AFP) of hepatocellular carcinoma, carcinoembryonic antigen (CEA) of colon cancer and prostate specific antigen of prostate cancer. This evidence concerns the gene CEACAM5 and prostate cancer.